YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

Fenofibrate-Induced Rhabdomyolysis in a Patient With Chronic Renal Failure Due To Nephrotic Syndrome: a Rare Case Report

dc.authorid Reha, Erkoc/0009-0001-7230-8843
dc.authorscopusid 49461096800
dc.authorscopusid 13105952900
dc.authorscopusid 36165464000
dc.authorscopusid 10242147700
dc.authorscopusid 54382862800
dc.authorscopusid 8409430500
dc.authorwosid Turan Canbaz, Esra/Kxs-1505-2024
dc.authorwosid Begenik, Huseyin/Lkl-8263-2024
dc.authorwosid Erdur, Fatih/Jsl-4491-2023
dc.contributor.author Erdur, Fatih Mehmet
dc.contributor.author Soyoral, Yasemin Usul
dc.contributor.author Emre, Habib
dc.contributor.author Begenik, Huseyin
dc.contributor.author Canbaz, Esra Turan
dc.contributor.author Erkoc, Reha
dc.date.accessioned 2025-05-10T16:46:54Z
dc.date.available 2025-05-10T16:46:54Z
dc.date.issued 2012
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp [Erdur, Fatih Mehmet; Emre, Habib; Begenik, Huseyin; Canbaz, Esra Turan] Yuzuncu Yil Univ, Fac Med, Dept Internal Med, TR-65000 Van, Turkey; [Soyoral, Yasemin Usul; Erkoc, Reha] Yuzuncu Yil Univ, Fac Med, Dept Nephrol, TR-65000 Van, Turkey en_US
dc.description Reha, Erkoc/0009-0001-7230-8843 en_US
dc.description.abstract Objectives: Fenofibrate is a fibric acid derivative that is used alone or combination with statins in the treatment of hyperlipidemia. These drugs have potential risks, including rhabdomyolysis and acute renal failure. Despite reports of rhabdomyolysis with the use of fenofibrate alone or with statin-fibrate combinations, there have been no cases of rhabdomyolysis described when fenofibrate was used alone to treat patients with chronic renal failure owing to nephrotic syndrome. Design and methods: We report on a 26-year-old male who presented with fenofibrate-induced rhabdomyolysis with chronic renal failure due to nephrotic syndrome. Results: After the discontinuation of fenofibrate, the patient was treated with intravenous fluid replacement and urine alkalization. Subsequently, his clinical and biochemical findings improved. Conclusions: Before starting fenofibrate therapy, the causes of secondary hyperlipidemia, especially nephrotic syndrome, should be investigated. In the presence of chronic renal failure and hypoalbuminemia, the fenofibrate dose should be adjusted. Physicians should be aware of the potential toxicities of fenofibrate, and patients should be informed about its potential side effects. (C) 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved. en_US
dc.description.woscitationindex Science Citation Index Expanded
dc.identifier.doi 10.1016/j.clinbiochem.2011.09.025
dc.identifier.endpage 164 en_US
dc.identifier.issn 0009-9120
dc.identifier.issn 1873-2933
dc.identifier.issue 1-2 en_US
dc.identifier.pmid 22019952
dc.identifier.scopus 2-s2.0-84855303936
dc.identifier.scopusquality Q2
dc.identifier.startpage 162 en_US
dc.identifier.uri https://doi.org/10.1016/j.clinbiochem.2011.09.025
dc.identifier.uri https://hdl.handle.net/20.500.14720/1295
dc.identifier.volume 45 en_US
dc.identifier.wos WOS:000299364800034
dc.identifier.wosquality Q2
dc.language.iso en en_US
dc.publisher Pergamon-elsevier Science Ltd en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Fenofibrate en_US
dc.subject Rhabdomyolysis en_US
dc.subject Chronic Renal Failure en_US
dc.subject Nephrotic Syndrome en_US
dc.title Fenofibrate-Induced Rhabdomyolysis in a Patient With Chronic Renal Failure Due To Nephrotic Syndrome: a Rare Case Report en_US
dc.type Article en_US

Files